CEO Zach Booker also praises Midwest as haven for startups

GRAND RAPIDS, Mich., April 17, 2023 (Newswire.com) - In two events at the recent SXSW Conference, ADHD Online, the leader in online ADHD testing and assessment, outlined the reasons for its exponential growth and addressed the unspoken prevalence of mental health issues for entrepreneurs.

"ADHD Online is based in Grand Rapids, Michigan, far from the entrepreneurial hotbeds of the U.S. coasts. But the Midwest is a powerhouse of talent, with unique opportunities, and ADHD Online leveraged the region's advantages," CEO Zach Booker told the crowd at the "Scaling in the Midwest" panel. "That allowed the company to grow to serve patients in all 50 states in just one year," Booker said.  

"Central to that success was the company's philosophy and structure, which allowed it to 'plug and play' a system that delivers and maintains a high standard of care for treating mental health patients in the same way regardless of where they live," Booker said.  

At the "Mental Health and Entrepreneurs" panel, Keith Brophy, ADHD Online's chief operating officer, outlined the increasing prevalence of mental health issues in the United States and among entrepreneurs in particular. According to the Centers for Disease Control, one in five Americans will experience a mental illness in a given year, while one in 25 lives with a serious mental illness.  

"Among the factors that can contribute to mental illness are adverse life experiences, substance abuse, trauma, loneliness and isolation - with the latter two being common problems among entrepreneurs as they create and launch their ventures," Brophy said, citing a number of studies. 

Entrepreneur Online reports found that one in four entrepreneurs will experience mental illness of some kind, with anxiety and depression the most common issues. A recent study found that 72% of entrepreneurs had mental health problems. And statistics from the National Institute for Mental Health show that entrepreneurs have depression at twice the rate of the general population, six times the rate of ADHD, three times the rate of bipolar disorder, and twice the rate of addiction. 

"Our panel really set the stage for entrepreneurs to be open in discussing their mental health and not hiding behind the mystique of entrepreneurs and leaders, where they can't be authentic about their mental health," Brophy said.  

"The mental health of entrepreneurs is overlooked, or even swept under the rug," Booker agreed. "There's an assumption that people have that entrepreneurs must be good at everything since they're in business for themselves. And the 'fake it until you make it' phenomenon means many entrepreneurs can't be honest about their struggles." 

To learn more about ADHD Online and Mentavi Health, visit https://adhdonline.com/. 

About ADHD Online

ADHD Online was founded in 2018 with the mission that everyone should have access to quality ADHD assessments regardless of who and where they are. The ADHD Online team is filled with industry experts across the United States who all share the same passion for ADHD and making sure patients have access to critical mental health services. ADHD Online is leading the way with being a critical voice for those who might be struggling with ADHD and is the only organization to offer HIPAA-secured ADHD assessments online with results from licensed psychologists. ADHD Online is active in all 50 states.

Contact Information:
Mike Albanese
[email protected]


Original Source: ADHD Online Leaders Address Hidden Issue of Entrepreneurs' Common Mental Health Challenges

HanchorBio Received IND Clearance of HCB101 Multi-regional Clinical Trial By US FDA

TAIPEI, Taiwan & SAN FRANCISCO, April 17, 2023 (Newswire.com) - HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.

Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio, commented, "Although there is demonstrated history of PD-1/PD-L1 immune checkpoint inhibitors showcasing strong efficacy in a variety of cancers and significantly improved the prognosis of certain cancer patients, there is a large percentage of cancer patients who are either refractory to these immunotherapies or develop resistance. HCB101 is our independently-developed leading candidate to block the "do not eat" signal from the SIRPα-CD47 pathway, sufficiently eliminating tumor cells by macrophage while exhibiting excellent safety profile in our preclinical studies. The FDA clearance of our first IND marks a significant milestone for HanchorBio and demonstrates our team's continuous focus and commitment to bringing novel immunotherapies to patients with significant unmet need."

"Based on our studies in 15 murine xenograft tumor models of solid and hematological malignancies, HCB101 has demonstrated superior anti-tumor efficacy, both as monotherapy and in combination with other agents. The advantage is even more apparent when comparing HCB101 with other agents targeting the same pathway currently being investigated in clinical trials," said Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio. "Unlike other CD47-blocking agents, HCB101 exhibits excellent safety profiles in the repeat-dose cynomolgus monkey toxicology studies, as no abnormality of RBC or platelet levels were observed. It is an important safety factor for differentiation. I look forward to advancing the clinical development of HCB101 and continuing the focus on patient-centric research and development to hopefully bring novel treatments with clinically meaningful benefits to patients as early as possible."

About HCB101

Using structure-guided protein design and engineering supplemented with relevant screening technologies, HCB101 is an engineered extracellular domain of SIRPα fused to the Fc region of IgG₄. HCB101 triggers phagocytic activity of the macrophages by blocking the "do not eat" signal between macrophages and tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a safer and more potent biologic than the anti-CD47 monoclonal antibodies and SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment comparing to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action.

About Multi-Regional Clinical Trial of HCB101

HCB101-101 is a multi-regional, multi-center, open-label, dose-finding, first-in-human (FIH) study of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. The purposes of the study are to evaluate the safety, tolerability, pharmacokinetics, and clinical anti-tumor activity of weekly HCB101 intravenous injections. The HCB101 IND is on track being reviewed by the Taiwan FDA.

About HanchorBio 

Based in Taipei, Shanghai, and San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with proven track-record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs. 

For more information, please visit: www.HanchorBio.com

or follow us on LinkedIn at www.linkedin.com/company/hanchorbio-inc

Contact Information:
Scott Liu
Founder, Chairman and CEO
[email protected]

Yi Du
Sr. Director of Business Development
[email protected]


Original Source: HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies

Real-time patient discharge information automatically populates the transitions of care dashboard, transforming Medicare TCM and CCM programs.

HOUSTON, April 17, 2023 (Newswire.com) - CrossTx, a leading care management cloud-based technology company serving Rural Health Clinics, Federally Qualified Health Centers and physician-owned clinics with C3HIE, a leading Texas-based health information exchange (HIE) in 129 Texas counties, announce exciting new functionality to a long-standing partnership. This novel approach utilizes the C3HIE Admission, Discharge, and Transfer (ADT) data-feed to support comprehensive Transitional Care Management (TCM) programs across Texas. The new functionality includes a comprehensive dashboard that auto populates discharged patient information from surrounding hospitals which provide a step-by-step transitional care workflow. Throughout the transition process, the software generates a patient specific report and patient population report, complete with audit trails. This collaborative service offering ensures proper care coordination tracking for TCM codes 99496 and 99495, supports ACO shared savings programs, and other quality-based initiatives.

The Centers for Medicare and Medicaid Services (CMS) TCM program helps improve patient outcomes in the transition from an inpatient or partial inpatient setting to community location. With the ADT data-feed from C3HIE, discharged patients are identifiable as well as filtered to focus on eligible Medicare Beneficiaries deemed at risk for readmission or other adverse events following hospitalization. C3HIE's data provides real-time information on patient discharge status. This data, when placed into CrossTx, supports patient progress while facilitating specific steps in the TCM program including 30 days of care coordination, any necessary adjustments to the care plan, provider chart and discharge review, medicine reconciliation, care coordinator chart and discharge review, documentation of the interactive call, and completed follow up visit within 7 or 14 days after discharge.

"We are excited to expand our partnership with C3HIE to develop a TCM program that improves patient outcomes and reduces healthcare costs," said Chad Nybo, CEO of CrossTx. "By utilizing the ADT data-feed from C3HIE, our TCM cloud-based service populates eligible patients, in real-time. Our client's care coordinators can now provide them with the support they need to transition from hospital to home smoothly."

C3HIE's ADT data-feed provides timely and accurate information on patient admissions, discharges, and transfers, making it an essential tool for care coordination. "We are thrilled to work with CrossTx to develop a TCM program that leverages our ADT data-feed to improve patient outcomes and reduce readmissions," said Jim Hoag, COO of C3HIE. "This integrated partnership leverages our provider connections in the HIE ecosystem giving providers revenue-generating tools to improve outcomes for less cost."

C3HIE and CrossTx have collaborated now for several years to support clinics, community health centers, and other healthcare facilities to develop Chronic Care Management (CCM) programs. CCM programs are designed to support patients with chronic conditions between visits with their provider. TCM programs can increase the enrollment of patients in CCM programs and thereby optimize patient outcomes, reducing costs, and addressing gaps in care within the community. The TCM dashboard would not be complete without a section dedicated to encouraging TCM patients to enroll in the facility's CCM program for long-term improvement.

About CrossTx: CrossTx is a healthcare technology company that is dedicated to improving the healthcare experience for patients and providers alike. With a focus on innovation and user-centered design, CrossTx develops care coordination solutions that make CMS programs such as Chronic Care Management and Transitional Care Management more efficient, accessible, and effective. www.crosstx.com

About C3HIE: C3HIE is a Texas-based, multi-region collaboration building the safe and secure infrastructure between healthcare providers' electronic health records (EHRs) making it possible to exchange information across different platforms. C3HIE offers customized health data sharing and analytics solutions aimed at hospitals, providers, health plans and patients that include real-time alerts, historical and predictive analytics, a longitudinal patient health record and community resource collaboration. http://www.C3HIE.org

Contact Information:
Chandra Donnell
VP Client Success
[email protected]
406.595.1326


Original Source: Texas Health Information Exchange, C3HIE Developed Transitional Care Management Dashboard With CrossTx